Personalis

Personalis FCF/Debt

The Free Cash Flow to Debt Ratio of Personalis (PSNL) as of Nov 4, 2026 is -983.05 %. In the previous year, Free Cash Flow to Debt Ratio was -2,638.43 % — a change of -62.74% (higher).

FCF/Debt

-983.05 %

YoY

-62.74%

Last updated:

Free Cash Flow to Debt Ratio of Personalis is 2025 -983.05 % . Free Cash Flow to Debt Ratio of Personalis was 2024 -2,638.43 % . It decreases by -62.74% higher compared to the previous year.

The Personalis FCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF/Debt
Date
FCF/Debt
Jan 1, 2017
-27.35 USD
Jan 1, 2018
-40.00 USD
Jan 1, 2021
-2,340.31 USD
Jan 1, 2022
-4,620.35 USD
Jan 1, 2023
-2,332.26 USD
Jan 1, 2024
-2,638.43 USD
Jan 1, 2025
-983.05 USD
The Personalis FCF/Debt history
YEARFCF/DebtYoY
-983.05 %-62.74%
-2,638.43 %+13.13%
-2,332.26 %-49.52%
-4,620.35 %+97.42%
-2,340.31 %+5,750.79%
-40.00 %+46.26%
-27.35 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Personalis Stock analysis

What does Personalis do? Personalis Inc is a diagnostic company specializing in the development of tests for personalized medicine. The company was founded in 2011 by Dr. Richard Chen and Dr. Erin Newburn and is headquartered in Menlo Park, California. They initially focused on developing genomic tools for cancer diagnosis and treatment but have expanded their offerings to include tests for rare genetic diseases, immunotherapies, and precision oncology drugs. They work closely with pharmaceutical and biotechnology companies as well as academics to develop innovative therapeutic approaches. Their business model is based on making genomics biology usable for personalized medicine and clinical research. They have a wide portfolio of genomic-based solutions for personalized medicine, including tests for tumor mutations, tumor-specific neoantigens, rare genetic diseases, and personalized immunotherapy. They also offer customized genomic solutions for pharmaceutical and biotechnology companies. Personalis Inc aims to establish personalized medicine quickly and effectively to provide the best possible outcome for patients. Personalis is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Personalis stock

Free Cash Flow to Debt Ratio of Personalis is -983.05 % in 2025.

Free Cash Flow to Debt Ratio of Personalis changed from -2,638.43 % to -983.05 %, representing a -62.74% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow to Debt Ratio Personalis since 2006 – with annual values, charts, and detailed analysis.

FCF/Debt measures the percentage of total debt that could be repaid from free cash flow. It is a stricter measure than OCF/Debt as it accounts for capital expenditures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow to Debt Ratio's Personalis with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Personalis

All Key Metrics — Personalis